125 related articles for article (PubMed ID: 8468919)
21. [Biocompatibility in long-term hemodialysis: facts--theories--clinical significance].
Bosch TH; Blumenstein M; Gurland HJ
Z Urol Nephrol; 1989 Feb; 82(2):69-76. PubMed ID: 2658418
[TBL] [Abstract][Full Text] [Related]
22. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
23. The production of platelet-activating factor (PAF) during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it?
Iatrou C; Afentakis N; Antonopoulou S; Andrikopoulos N; Demopoulos CA; Ziroyannis P
Int J Artif Organs; 1995 Jul; 18(7):355-61. PubMed ID: 8655220
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of platelet lipoxygenase during hemodialysis.
Foidart JB; Davin JC; Malaise M; Saint-Remy M; Mahieu P
Kidney Int Suppl; 1988 Mar; 24():S80-1. PubMed ID: 3163058
[No Abstract] [Full Text] [Related]
25. The role of platelet-activating factor in the haemoincompatibility of haemodialytic treatments.
Tetta C; Wratten M; Cristol JP; Tarchini R; Bosc JY; Canaud B; Camussi G
Int J Artif Organs; 1998 Nov; 21(11):693-8. PubMed ID: 9894743
[No Abstract] [Full Text] [Related]
26. Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system.
Koller H; Hochegger K; Zlabinger GJ; Lhotta K; Mayer G; Rosenkranz AR
Nephrol Dial Transplant; 2004 Dec; 19(12):3104-11. PubMed ID: 15575000
[TBL] [Abstract][Full Text] [Related]
27. Involvement of platelet-activating factor in cytokine production and neutrophil activation after hepatic ischemia-reperfusion.
Serizawa A; Nakamura S; Suzuki ; Baba S; Nakano M
Hepatology; 1996 Jun; 23(6):1656-63. PubMed ID: 8675190
[TBL] [Abstract][Full Text] [Related]
28. The production of platelet-activating factor during hemodialysis.
Tetta C; Segoloni G; Pacitti A; Regis G; Salomone M; Turello E; Camussi G; Vercellone A
Int J Artif Organs; 1989 Dec; 12(12):766-72. PubMed ID: 2613357
[TBL] [Abstract][Full Text] [Related]
29. Cytokine and lipid inflammatory mediator profile of human tears during contact lens associated inflammatory diseases.
Thakur A; Willcox MD
Exp Eye Res; 1998 Jul; 67(1):9-19. PubMed ID: 9702174
[TBL] [Abstract][Full Text] [Related]
30. Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysis.
Akizawa T; Kinugasa E; Koshikawa S
ASAIO Trans; 1991; 37(3):M384-5. PubMed ID: 1751199
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms of acute leukopenia in hemodialysis. Role of direct leukocyte and dialyzer membrane interaction].
Pacitti A; Segoloni G; Triolo G; Tetta C; Messina M; Bussolino F; Camussi G; Ragni R; Martini PF; Coppo R; Vercellone A
Minerva Nefrol; 1980; 27(4):651-3. PubMed ID: 7254693
[No Abstract] [Full Text] [Related]
32. Polymorphonuclear granulocyte stimulation by cellulose-based hemodialysis membranes.
Körmöczi GF; Rosenkranz AR; Zlabinger GJ
Clin Chem Lab Med; 1999 Mar; 37(3):351-5. PubMed ID: 10353482
[TBL] [Abstract][Full Text] [Related]
33. Increases in circulating level of platelet-activating factor lag behind transient neutropenia during hemodialysis with cuprophane membranes.
Sakaguchi K; Morimoto S; Chen YH; Nakamoto Y; Ogihara T
Nephron; 1991; 59(3):455-60. PubMed ID: 1758537
[TBL] [Abstract][Full Text] [Related]
34. Side effects of hemodialysis.
Eknoyan G
N Engl J Med; 1984 Oct; 311(14):915-7. PubMed ID: 6472405
[No Abstract] [Full Text] [Related]
35. The role of platelet-activating factor in the biocompatibility of hemodialysis membranes.
Tetta C; Haeffner-Cavaillon N; Navino C; David S; Franceschi C; Mariano F; Camussi G
Adv Exp Med Biol; 1996; 416():243-8. PubMed ID: 9131156
[No Abstract] [Full Text] [Related]
36. Biocompatibility of hemodialysis membranes.
Cheung AK
J Am Soc Nephrol; 1990 Aug; 1(2):150-61. PubMed ID: 2104259
[TBL] [Abstract][Full Text] [Related]
37. Effects of PAF on neutrophils and mononuclear phagocytes.
Baggiolini M; Dewald B; Thelen M
Prog Biochem Pharmacol; 1988; 22():90-105. PubMed ID: 3043438
[No Abstract] [Full Text] [Related]
38. A review of the concept of biocompatibility.
Schulman G
Kidney Int Suppl; 1993 Jun; 41():S209-12. PubMed ID: 8320923
[TBL] [Abstract][Full Text] [Related]
39. PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection.
Braquet P; Paubert-Braquet M; Bourgain RH; Bussolino F; Hosford D
J Lipid Mediat; 1989; 1(2):75-112. PubMed ID: 2519889
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo model for pre-clinical evaluation of dialyzers containing new membranes.
Mahiout A; Meinhold H; Jörres A; Krieg R; Kessel M; Tretzel J; Baurmeister U
Life Support Syst; 1985; 3 Suppl 1():448-52. PubMed ID: 3879954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
